Table1 Characteristics of patients admitted to ICU with univariate comparisons.

From: Risk factors for bloodstream infection among patients admitted to an intensive care unit of a tertiary hospital of Shanghai, China

Patients characteristics

Bloodstream infection patients (n = 71) n(%)/median (IQR)

Without bloodstream infection patients (n = 200) n (%)/median (IQR)

Univariate analysis

OR (95% CI)

p value

Demographics

 Male

54 (76.06)

136 (68.00)

1.004 (0.555–1.817)

0.990

 Age

74 (65–84)

69.5 (56–78)

0.072

 Fever (≥ 38 °C)

40 (56)

123 (62)

0.808 (0.467–1.398)

0.445

Chronic comorbidity

 COVID-19

12 (17)

21 (11)

1.734 (0.804–3.736)

0.156

 Gastrointestinal

43 (61)

95 (48)

1.697 (0.978–2.945)

0.059

 Respiratory

44 (62)

105 (53)

1.474 (0.848–2.565)

0.168

 Cardiovascular

31 (44)

81 (41)

1.139 (0.659–1.968)

0.642

 Renal

28 (39)

83 (42)

0.918 (0.528–1.596)

0.761

 Neurologic

23 (32)

101 (51)

0.470 (0.266–0.830)

0.009*

 Metabolic disorders

45 (63)

118 (59)

1.203 (0.688–2.104)

0.517

 Immunocompromise

12 (16.9)

43 (21.5)

0.743 (0.366–1.505)

0.408

Severity at BSI onset

 Shock

46 (65)

83 (42)

2.594 (1.478–4.552)

0.001*

 APACHE II score > 15

47 (66.2)

130 (65)

1.054 (0.596–1.867)

0.856

Treatment interventions before infections events

 Surgical intervention

33 (46)

75 (38)

1.436 (0.830–2.482)

0.194

 Enteral feeding

44 (62)

151 (76)

0.529 (0.297–9.942)

0.029*

 Trauma

6 (8)

20 (10)

0.831 (0.320–2.160)

0.703

 Gastrointestinal bleeding

15 (21)

19 (10)

2.552 (1.217–5.350)

0.011*

 Transfusion

39 (55)

88 (44)

1.551 (0.900–2.674)

0.113

 Dialysis therapy

29 (41)

54 (27)

1.867 (1.059–3.291)

0.03*

 Tracheotomy

25 (35.2)

31 (15.5)

2.963 (1.595–5.505)

 < 0.001*

 Ventilator

47 (66.2)

145 (72.5)

0.743 (0.415–1.329)

0.315

 Central venous catheter

53 (74.6)

132 (66)

1.517 (0.825–2.790)

0.179

Outcome

Length of stay

 Total hospital stay (d)

30 (13–53)

21 (11–35)

 < 0.001*

 ICU stay (d)

21 (8–41)

15 (8–26)

 < 0.001*

 Mortality

25 (35.21)

40 (20)

2.174 (1.196–3.952)

0.01*

Laboratory parameter

 Alkaline phosphatasea

102.5 (75.75–173.5)

81 (58–113)

0.005*

 Alanine transaminasea

34 (15–85)

27 (13–55.75)

0.951

 Aspartate aminotransferasea

44 (26–89)

39 (20–80)

0.64

 γ-glutamyl transpeptadasea

61 (40–121)

33 (20–87.5)

0.013*

 Total bilirubin levelb

22.9 (15.2–56)

17.3 (10.93–30.45)

0.095

 Direct bilirubinb

8.2 (4.3–31.9)

5.3 (2.93–11.48)

0.099

 Total biliary acidb

5.55 (3.18–16.58)

4.1 (2.3–8.5)

0.263

 Cholyglycineb

3.1 (1.8–9.9)

2 (1.5–3.9)

0.067

 Total proteinc

59.5 (51.5–66.25)

58 (52.25–63)

0.298

 Serum creatinine levelb

105 (71–154)

92 (66–158.75)

0.975

 Brain natriuretic peptided

698 (237.75–1599.25)

273 (104.5–856.5)

0.02*

 Procalcitonine

6.34 (1.23–52)

0.69 (0.24–3.85)

 < 0.001*

 Hematocrit

0.27 (0.21–0.34)

0.3 (0.25–0.34)

0.022*

 Hemoglobinc

87 (70–113)

98 (82–115.75)

0.008*

 Leukocyte countf

9.3 (6.54–18.12)

11 (7.41–14.29)

0.788

 Neutrophil countf

8.16 (5.62–17.21)

9.41 (6.18–12.41)

0.328

 Lymphocyte countf

0.58 (0.33–0.98)

0.69 (0.45–1.04)

0.547

 Monocyte countf

0.3 (0.17–0.62)

0.48 (0.28–0.76)

0.08

 Mean platelet volume (fl)

10.8 (9.88–12.13)

10.3 (9.4–11.3)

0.003*

 Platelet countf

113 (44–203)

151 (102–220)

0.023*

 Erythrocyte countf

2.91 (2.23–3.66)

3.24 (2.68–3.89)

0.017*

 CRP (mg/L)

143.5 (93–200)

96.5 (40.25–164.75)

 < 0.001*

Antibiotic usage

 Antifungal agents

30 (42)

123 (62)

0.458 (0.264–0.794)

0.005*

 Fluoroquinolone

24 (34)

71 (36)

0.928 (0.524–1.642)

0.797

 Peptide antibiotic

30 (42)

110 (55)

0.599 (0.346–1.035)

0.065

 Cephalosporin

35 (49)

153 (77)

0.299 (0.169–0.527)

 < 0.001*

 Carbapenem

52 (73)

152 (76)

0.864 (0.466–1.603)

0.643

 Tigecycline

13 (18)

14 (7)

2.978 (1.324–6.697)

0.006*

 Linezolid

21 (30)

75 (38)

0.700 (0.390–1.256)

0.231

  1. a U/L bμmol/L cg/L dpg/ml eng/mL f109/L.
  2. *p < 0.05.